Core Viewpoint - Vertex Pharmaceuticals forecasts 2026 revenue largely in line with analysts' estimates, driven by growth in cystic fibrosis treatments and contributions from newer products [1] Group 1: Revenue Forecast - The company anticipates revenue for 2026 to align closely with analyst expectations [1] - Growth is expected primarily from cystic fibrosis treatments [1] Group 2: Product Contributions - Newer products are also expected to contribute to the revenue growth [1]